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Objectives: To estimate the health and economic beneﬁts that would result from two scenarios of
improved air quality in 57 municipalities of the metropolitan area of Barcelona.
Methods: We used attributable fractions and life tables to quantify the beneﬁts for selected health
outcomes, based on published concentration-response functions and economic unit values. The mean
weighted concentration of PM10 for the study population was estimated through concentration surface
maps developed by the local government.
Results: The annual mean health beneﬁts of reducing the mean PM10 exposure estimated for the
population in the study area (50mg/m3) to the annual mean value recommended by the World Health
Organization (20mg/m3) were estimated to be 3,500 fewer deaths (representing an average increase in life
expectancy of 14 months), 1,800 fewer hospitalizations for cardio-respiratory diseases, 5,100 fewer cases of
chronic bronchitis among adults, 31,100 fewer cases of acute bronchitis among children, and 54,000 fewer
asthma attacks among children and adults. The mean total monetary beneﬁts were estimated to be 6,400
million euros per year. Reducing PM10 to comply with the current European Union regulatory annual mean
level (40mg/m3) would yield approximately one third of these beneﬁts.
Conclusions: This study shows that reducing air pollution in the metropolitan area of Barcelona would
result in substantial health and economic beneﬁts. The beneﬁts are probably underestimated due to the
assumptions made in this study. Assessment of the health impact of local air pollution is a useful tool in
public health.
& 2008 SESPAS. Published by Elsevier Espan˜a, S.L. All rights reserved.Estimacio´n de los beneﬁcios en salud y econo´micos asociados a la reduccio´n de
la contaminacio´n atmosfe´rica en el a´rea metropolitana de Barcelona (Espan˜a)Palabras clave:
Contaminacio´n atmosfe´rica
Evaluacio´n impacto en salud
Medicina preventiva
Casos atribuibles
Evaluacio´n monetariaR E S U M E N
Objetivos: Se presenta una estimacio´n de los beneﬁcios para la salud y econo´micos de dos escenarios de
mejora de la calidad del aire ambiental en 57 municipios del a´rea metropolitana de Barcelona.
Me´todos: Usando fracciones atribuibles y tablas de vida, se cuantiﬁcaron los beneﬁcios para los
indicadores de salud seleccionados basa´ndose en funciones de concentracio´n-respuesta y en unidades
monetarias publicadas. La concentracio´n media ponderada de PM10 para la poblacio´n del estudio se obtuvo
mediante mapas de concentraciones desarrollados por el gobierno local.
Resultados: Los beneﬁcios anuales de reducir la exposicio´n media a PM10 estimada para la poblacio´n del
a´rea de estudio (50mg/m3) al valor anual medio recomendado por la Organizacio´n Mundial de la Salud
(20mg/m3) se estiman en 3.500 muertes menos (representando en media un aumento de la esperanza de
vida de 14 meses), 1.800 ingresos hospitalarios menos por causas cardiorrespiratorias, 5.100 casos menos
de bronquitis cro´nicas en adultos, 31.100 casos menos de bronquitis agudas en nin˜os y 54.000 crisis
asma´ticas menos en nin˜os y adultos. Los beneﬁcios econo´micos totales se estiman en una media de 6.400
millones de euros por an˜o. Reducir las PM10 al nivel anual medio legislado por la Unio´n Europea (40mg/m3)
representarı´a aproximadamente una tercera parte de estos beneﬁcios.
Conclusiones: Este estudio indica que reducir la contaminacio´n atmosfe´rica en el ae´rea metropolitana de
Barcelona resultarı´a en beneﬁcios en salud y econo´micos muy sustanciales. Una infravaloracio´n es probable
debido al enfoque metodolo´gico tomado. Las evaluaciones de impacto en salud son herramientas u´tiles en
salud pu´blica.
& 2008 SESPAS. Publicado por Elsevier Espan˜a, S.L. Todos los derechos reservados.Introduction
Experimental studies conducted in cellular models, animals
and humans, and numerous epidemiological studies have shown
that short-term and long-term exposure to current levels ofado por Elsevier Espan˜a, S.L. Todoanthropogenic air pollution lead to morbidity and mortality in
humans1,2.
In the last decade, scientists and public health agencies have
translated these research ﬁndings into quantities that reﬂect the
burden on health attributable to air pollution in a given region,
country, or city3–5. This process is important because it directly
informs policy makers and the public about the current situation
or the impact of future or past air pollution policies. Regional
studies have also been used as tool for prioritizing national
regulation and policy development. Given that every society hass los derechos reservados.
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health quantities be transformed into monetary valuations to be
compared with mitigation investments. Thus, valuation of health
effects is a critical component of health impact assessment (HIA)6.
Air quality characterized by the inhalable fraction of particu-
late matter (PM10), nitrogen dioxide (NO2) and other pollutants is
poor in the Barcelona metropolitan area, with trends in recent
years showing progressive degradation7. In 2007, when the local
government initiated actions to reduce air pollution, questions
arose about the potential health and economic beneﬁts of
abatement strategies. Air pollution burden for Spain and Barce-
lona has been partially estimated by different European stu-
dies8–10. An assessment of 26 European cities estimated that
reducing PM2.5 levels in the city of Barcelona would decrease the
numbers of deaths among people aged 30 years and over from
1.5% (95% conﬁdence interval [CI]: 0.4%–3.0%) to 5.4% (95%CI:
1.4%–10.4%)8. In Spain, only one study has incorporated cost into
this type of evaluation10. Comparing year 2000 emission levels to
current legislation, this study estimated that air pollution caused
morbidity diseases and approximately 22,000 premature deaths.
This impact translated into a total cost of 400 to 1,000 euros per
year per capita, depending on the method of calculation selected.
This article estimates the health and economic beneﬁts
associated with reducing air pollution in the Barcelona metropo-
litan area from current levels to the European Union (EU)
standards and World Health Organization (WHO) targets. Few
HIAs have analyzed air pollution burden at the community level,
although local analysis might lead to better decision making. This
study demonstrates how HIA may support public health policy at
a scale that reﬂects conditions for the community for which
policies will be designed or implemented.Methods
This study follows standard methodology to derive the risk
attributable to outdoor air pollution10. The methods require the60
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Figure 1. Average PM10 concentrations in urbanized areas of the 57 municipalitiesfollowing information: selection of study area, exposure assess-
ment, health-outcomes, concentration-response functions, sce-
nario of change in exposure considered, and unit monetary values.
Study area
We selected as area of study a continuous geographic area
constituted by a total of 57 municipalities, including the
municipality of Barcelona. For the purpose of our study, we
denominated this area )Barcelona metropolitan area*. This study
area includes a total population of 3,868,663 inhabitants (year
2004). The municipality level reﬂects the smallest political unit
for which routine health data (i.e. mortality data and hospital
admission data) were available. This area was selected for its
geographical continuity and potential uniformity in terms of air
pollution exposure. Figure 1 presents the 57 municipalities
included in the study area with population per 1,000 for 2004.
Characterizing pollution
Air pollution is a complex mixture of often highly correlated
constituents and pollutants2. Health impact assessments of air
pollution rely on epidemiological studies, using one marker of air
quality because it is not appropriate to sum the risk for correlated
pollutants11. For this study, we selected PM10 as marker of air
pollution to follow the approach used in other HIAs4,12 and based
on the availability of exposure data for the area of study.
To derive beneﬁts for a speciﬁc change in air pollution is
necessary to determine the level of exposure of the population
before changes occur. We considered the current levels as the
point of reference for future changes. The population exposure for
PM10 was represented by an average population-weighted con-
centration derived from a PM10 concentration surface map
developed by local authorities. This map estimated 2004 spatial
concentration of PM10 through dispersion models that took into
account emission sources. Modeled surfaces were validated by
comparing concentration levels at ﬁxed monitoring sites with9)
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included in the area of study (population per 1000 for 2004 in parenthesis).
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Table 1
Health outcomes (number or percentage) and concentration-response functions in the area of study
Outcome Age Population baseline frequency/number PM10 concentration-response function
Number or percent Source Mean (95%CI)
per 10mg/m3
Sourcea
Mortality
Infant death (ICD10 A00-R99) o1 117 Catalonian mortality registry 2004 1.048
(1.022–1.075)
Pooled estimate reported in
Lacasan˜a, et al (2005)16
Short-term effects all causes (ICD10
A00-R99)
All 29,473 Catalonian mortality registry 2004 1.006
(1.004–1.008)
Pooled estimate reported in
WHO, (2004)15
Long-term effects all causes (ICD10
A00-R99)
X30 29,187 Catalonian mortality registry 2004 1.043
(1.026–1.061)
Pooled estimate reported in
Ku¨nzli et al. (2000)4
Hospital admissions
Hospital admission for respiratory
diseases (ICD9 460-519)
All 34,593 CMBDAH Area of Barcelona 2004 1.011
(1.006–1.017)
APHEIS 3, 200512
Hospital admission for
cardiovascular diseases (ICD9
390-429)
All 35,080 CMBDAH Area of Barcelona 2004 1.006
(1.003–1.009)
Le Tertre et al. (2002)17
Morbidity
Chronic diseases
Chronic bronchitis adults X25 0.71% Study ASHMOG United States 1977–1987 1.098
(1.009–1.194)
Abbey et al. (1993)14
Acute bronchitis children o15 12.2% Study SCARPOL Switzerland 1992–1993 1.306
(1.135–1.502)
Pooled estimate reported in
Ku¨nzli et al. (2000)4
Asthma related symptoms
Asthma attacks adults X15 Asthmatics: 8.1% Average
number attacks/year: 1.4
Study ECHRS II Barcelona 1992–1995 1.039
(1.019–1.059)
Pooled estimate reported in
Ku¨nzli et al. (2000)4
Asthma attacks children o15 Asthmatics: 7.2% Average
number attacks/year: 3
Study SARI 2000–2001 Barcelona Study
SCARPOL 1992–1993 Switzerland
1.041
(1.020–1.051)
Pooled estimate reported in
Ward and Ayres (2004)13
CMBDAH: Registre del Conjunt Mı´nim Ba`sic de Dades de l’Alta Hospitala`ria; SCARPOL: Swiss Surveillance Program of Childhood Allergy and Respiratory Symptoms;
ASHMOG: Adventist Health and Smog; ECHRS: European Community Respiratory Health Survey; SARI: Estudi sobre Salut Respirato`ria a la Infa`ncia.
a Refers to study in which derivation of pool estimated was undertaken.
L. Pe´rez et al. / Gac Sanit. 2009;23(4):287–294 289predicted concentrations7. This modeled surfaces are used by local
authorities to develop air pollution mitigation strategies in the
study area. In the context of this study, the population exposure
is understood as the average concentration representative of
people’s residence. Several approaches are available to determine
population exposures depending on the level of detail of the data
available. No detailed population distribution was available for
our area of study. The estimated population exposure was thus
obtained by calculating municipality mean concentrations in
urbanized areas based on the government surface map. These
means were weighted by the population of each municipality to
obtain an average concentration interpreted as the average
exposure concentration for the area of study.
Health-outcomes and concentration-response functions
Three main families of health outcomes were evaluated:
mortality, morbidity including chronic bronchitis and asthma
related symptoms, and health care use represented by hospital
admissions for cardiovascular and respiratory diseases. The
association between outdoor air pollution and health-outcome
frequency is described with a concentration-response function
(CRF). We selected CRF from peer-reviewed literature used in
other HIAs4,12–17. Some of this CRF were expressed for other size
fractions of particulate matter (PM), mainly PM2.5 or Total
Suspended Particles, rather than PM10. When needed, conversion
factor of 1/0.6 and 0.6 was used to transform levels of PM2.5 or
Total Suspended Particles into PM10, respectively
4. Demographic
and baseline frequencies of health outcomes were obtained from
local health and statistics authorities or, when needed, extra-
polated from studies conducted in Europe (Table 1). Character-
istics and limitations of the input information are discussed later
in the text.Scenario of change in exposure
We provided risk estimates for two scenarios to reﬂect the
stepwise improvements of air quality expected in the area. The
main scenario estimated the ultimate beneﬁts for health if air
quality characterized by PM10 was in compliance with the air
quality guidelines recommended by the WHO. WHO recommends
a mean annual level for PM10 of 20mg/m3 or less to protect human
health2. The second scenario estimated health beneﬁts for an
intermediate step of air pollution abatement, namely reducing
current PM10 levels to the EU air quality standard. The EU
regulation states that PM10 levels should not have exceeded a
mean annual level of 40mg/m3 since 2005. This is the year 2010
target of current local policy efforts because the current EU limit
has not yet been met in several areas of Catalonia. In the context
of this study, the WHO and the EU limit values are interpreted as
average population exposure since limit values apply to any point
of the territory.
Derivation of attributable number of cases
We expressed results as the number of attributable cases for
the change of exposure under consideration. Within this evalua-
tion, attributable cases are interpreted as the number of health
events that could be prevented per year if air pollution was
reduced. Attributable cases were derived from attributable
population fractions applied to number of outcome cases in the
population. All calculations were conducted at the aggregated
level of the study area. Attributable fractions were derived with
the standard formula AFpop ¼ [pp (RR1)]/[pp (RR1)+1], where
pp represents the fraction of the population exposed to air
pollution and assumed as one, and RR represents the relative risk
(RR) of the CRF for the change in PM10 exposure considered. RR is
ARTICLE IN PRESS
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for 1mg/m3 and DC the change in exposure considered in mg/m3.
The statistical models used to derive CRFs most often provide odds
ratios (OR) from logistic regression models rather than RR. For
rare events or small effects, RR and OR are similar. However, for
frequent events and when the OR is large, OR may overestimate
the true RR. To take this into account, we corrected OR with a
standard formula18.
Derivation of life years lost
The concept of attributable or preventable death is concep-
tually ﬂawed as death is ultimately not preventable but can only
be postponed. Those exposed to lower pollution would in fact
have, in average, a longer life expectancy due to reduction in death
rates. We estimated average increase in life expectancy for our
study population using standard life table methods19.
Monetary valuation of health beneﬁts
Economists in different settings have attempted to develop
alternative measures of values for beneﬁts arising from clean
air20. Ideally these measures should represent all the losses to
individuals and to society that result from adverse health effects,
and reﬂect preferences and decision-making processes similar to
those of daily life20. In this evaluation, the value to attach to a
reduction of the risk of death and other end points were based on
the Willingness-To-Pay (WTP) approach. Unit monetary values
based on WTP are derived from market choices that reduce risk to
health or life indirectly20. We used same monetary values as those
proposed in the air pollution European cost-beneﬁt analysis and
derived from empiric studies10. In this evaluation, a mean and–120 –60 0
Percent change on central
(1) Upper and lower bound of CRF
(2) Alternative CRFs
(3) Potential errors in baseline
frequencies
(4) Alternative WTP ranges and
monetary valuation approach
D
C
C
A
A
C
T
Figure 2. Sensitivity of results expressed as percent change from the central point estim
and lower bound of the 95% of CRF; (2) use of central estimate of alternative CRFs; (3)
valuation range and approach.
ACS: American Cancer Society; CB: chronic bronchitis; CC: chronic cough; CVD: cardiov
Resp: respiratory; VOLY: value of life year; WTP: willingness-to-pay.
Reference for alternative CRFs: 1Pope et al. (2002)35;2Jerret et al. (2005)30;3WHO (2004)
et al. (1989)23;8Dusseldorp et al. (1995)24;9Roemer et al. (1993)25;10CAFE (2005)10.median value are proposed for some outcomes. Since no
consensus has been reached as to which value reﬂects better the
value of health,10 we used a single mid monetary unit in the core
estimates and discussed the impact of the variability of values in
the sensitivity analysis. Values were transformed to 2006-price
year using the real gross domestic product average annual
increase for Spain21. Economic beneﬁts were calculated multi-
plying the unit monetary value by the number of attributable
cases obtained for each scenario.
Expression of uncertainty
The various steps described above come with a range of
assumptions and uncertainties, which differ for the different
outcomes. To reﬂect these uncertainties results are presented with
a point estimate as well as an upper and lower bound given by the
95%CI of the CRF. For other uncertainties and assumptions, a series
of sensitivity analyses were conducted to assess the differences
between our mean results and results under alternative assump-
tions. Figure 2 summarizes the percent change that would have
applied to our central beneﬁts of the different health point studied
if alternative assumptions had been selected. Alternative assump-
tions were grouped into four: use of the upper and lower bound of
the 95%CI of CRF; use of other CRFs; assuming some error in the
baseline frequencies used; and use of alternative monetary values
or approach.Results
Based on the 2004 concentration surface maps, PM10 mean
average concentrations for the study area was 43mg/m3, ranging60 120
 estimate of the benefits
Deaths, long-termeffects
Deaths, inmediate acute effects
Infant deaths
Respiratory hospital admissions
CVD hospital admissions
CB in adults
Acute bronchitis in children
Asthma at tacks in adults
Asthma at tacks in children
eaths, long-term effets1 Deaths, long-term  effets, CRF from ACSLos Angeles2
Inmediate acute deaths, CRF city specific3
Resp hospital admissiones, CRF city spesific4
VD hospital admissions, CRF city specific5
B in adults, re-analysis6
cute bronchitis in children, CRF for CC7
Asthma attacks in adults, CRF for LRS8
sthma attacks in children, CRF for LRS9
B in adults, incidence with remission10
Acute bronchitis in children, ± 20% estimate
Asthma at tacks in adults, ± 20 estimate
Asthma at tacks in children, ± 20 estimate
Attributable dealths, range WTP estimate
CB in adults, range WTP estimate
otal benefits, estamation with VOLY
ate of the beneﬁts obtained for the different end-points studied. (1) Use of upper
assuming some error in the baseline frequencies used; (4) use different monetary
ascular; CRF: concentration response function; LRS: lower respiratory symptoms;
15;4Medina et al. (2005)12;5Le Tertre et al. (2002)17;6Abbey et al. (1995)22;7Dockery
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Table 2
Expected health beneﬁts per year for an annual reduction of PM10 in the area of study
Outcome Agea Health beneﬁts (95%CI)
Decrease to annual mean concentration of 20mg/m3 Decrease to annual mean concentration of 40mg/m3
Attributable number of cases % of total cases Attributable number of cases % of total cases
Mortality
Infant death
All causes o 1 15 (7–22) 13 (6–19) 5 (2–7) 4 (2–26)
Death due to short-term exposure (acute)
All causes All 520 (350–690) 2 (1–2) 180 (120–230) 0.6 (0.4–0.8)
Total death (long-term exposure; includes above acute effect)
All causes X 30 3,500 (2,200–4,800) 12 (7–16) 1,200 (760–1,700) 4 (3–6)
Hospital admissions
Respiratory causes All 1,150 (630–1,670) 3 (2–5) 390 (210–570) 1.1 (0.6–2)
Cardiovascular causes All 620 (310–930) 2 (1–3) 210 (110–310) 0.6 (0.3–0.9)
Morbility
Chronic diseases
Chronic bronchitis adults X25 5,100 (550–8,500) 25 (3–41) 1,900 (190–3,400) 9 (1–17)
Acute bronchitis children o15 31,100 (17,500–40,500) 49 (28–64) 12,100 (6,100–17,400) 19 (10–27)
Asthma related symptoms
Asthma attacks adults X15 41,500 (21,000–60,500) 11 (6–16) 14,700 (7300–21,800) 4 (2–6)
Asthma attacks children o15 12,400 (6,400–15,200) 11 (6–14) 4,000 (2100–5,000) 4 (12–5)
a Applies to population with age deﬁned by concentration-response function.
Table 3
Monetized beneﬁts per year for an annual reduction of PM10 in the area of study
Health outcomes Unit value in Eurosa PM10 annual mean reduction to 20mg/m3 PM10 annual mean reduction to 40mg/m3
Million of Euros per
year (95%CI)
% total beneﬁts
(95%CI)
Million of Euros per
year (95%CI)
% total beneﬁts
(95%CI)
Mortality
Attributable deathsb Median: h1,020,000/
death
5,400 (3,400–7,400) 84% (82%–97%) 1,900 (1200–2700) 83% (82%–100%)
Mean: h2,080,000/death
Morbidity
Hospital admissions h2,100/admission 3.7 (2.0–5.4) o1% 1.3 (0.7–1.8) o1%
Chronic bronchitis (adults)b Median: h125,000/case 970 (100–1,600) 15% (3%–18%) 360 (40–700) 16% (3%–20%)
Mean: h260,000/case
Total asthma symptoms h39/day 2.1 (1.1–3.0) o1% 0.7 (0.4–1.1) o1%
Total monetized beneﬁts 6,400 (3,500–9,000) 100% 2,300 (1,200–3,300) 100%
a Transformed to 2006 price-year.
b Use of mid value estimates to monetize beneﬁts.
L. Pe´rez et al. / Gac Sanit. 2009;23(4):287–294 291between 35 and 56mg/m3 depending on the municipality.
The highest mean concentrations were observed for municipa-
lities with the highest number of inhabitants (i.e municipality
of Barcelona) (Fig. 1). For the study area, we estimated a PM10
average exposure concentration of 50mg/m3 representative for a
population of approximately four million inhabitants (all ages).
Following the traditional approach of reporting the burden
of disease of air pollution by attributable deaths, we estimated
that approximately 3,500 (95%CI: 2,200–4,800) annual deaths,
about 12% (95%CI: 7–16) of all natural deaths, could be reduced if
outdoor air pollution was reduced to levels recommended by the
WHO (Table 2). We estimated that this translates to an average 14
months increase in life expectancy (95%CI: 6–22 months). In
addition, we estimated that there could be nearly 1800 (95%CI:
670–2,100) fewer hospitalization for cardio-respiratory diseases;
5,100 (95%CI: 550–8,500) fewer cases of chronic diseases in
adults; 31,100 (95%CI: 17,500–40,500) fewer cases of acutebronchitis in children; and approximately 54,000 (95%CI:
27,400–75,700) fewer asthma attacks in adults and children if
exposure to air pollution was reduced to the levels recommended
by the WHO. One third of the beneﬁts of the WHO scenario could
already be obtained if air pollutionwas decreased to EU regulatory
levels. Because the associations between air pollution and the
health outcomes considered in this study are linear, these latter
beneﬁts can also be interpreted as the intermediate beneﬁts that
would be obtained per each decrease of 10mg/m3 of ambient
concentrations in the area of study.
Results of the monetary valuation (Table 3) showed that,
the estimated total aggregated economical beneﬁts were 6,400
million Euros (95%CI: 3,500 to 9,000 million Euros) translating to
per capita beneﬁts of 1,600 euros (95%CI: 870–2,300) per year for
the WHO scenario. Total economical beneﬁts would amount to
2,300 million euros (95%CI: 1,200–3,300) per year if air pollution
was decreased to EU regulatory levels. More than 80% of the
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attributable deaths.Discussion
This assessment indicates that health and economical beneﬁts
would be substantial if air pollution was reduced in the Barcelona
metropolitan area. HIA provides a framework to evaluate the
relevance of community-based policy decisions to public health.
However, assumptions and uncertainty concerning methods must
be considered when interpreting results.
In this study, we made several assumptions that most likely
have underestimated the beneﬁts of reducing air pollution. First,
we selected PM10 as a marker of air pollution. Recent European
assessments have used smaller fractions of PM, speciﬁcally
PM2.5
3,8. Although variations may occur depending on location
and hour of the day, PM2.5 and PM10 in the Barcelona metropolitan
area are relatively highly correlated,26 thus results of a PM2.5
based assessment are expected to be similar. However, we ignored
effects and interactions with other pollutants that may have
independent effects2. In particular, effects of ozone (O3) were not
included. A recent report of the US Academy of Sciences
recommended the use of acute effects of ambient O3 in risk
assessment27. Also, recent research indicates that pollutants
which occur in very high concentrations close to busy streets,
e.g. the ultraﬁne fraction of PM, may have a particularly
detrimental effect on health28. PM10 does not capture these
trafﬁc-related exposure differences within Barcelona, thus our
estimation may not fully reﬂect these effects. The future
availability of concentration surfaces for PM2.5 or even the ﬁner
fraction of PM such as ultraﬁne would be an important
contribution to this health impact assessment. Second, air
pollution has adverse health effects (i.e. self-medication, re-
stricted activity days, cardiovascular diseases, etc) not included in
this assessment due to incomplete data2. Third, we have assumed
that air pollution is a risk factor for acute asthma attacks only.
While not conclusive, several studies indicate that air pollution, in
particular trafﬁc emissions, may lead to onset of asthma in
children28. Therefore, we may have underestimated the public
health beneﬁts of reducing both acute and chronic effects29.
Fourth, recent studies indicate that the CRF for long-term effects
of air pollution on mortality, which we used in this study, may be
an underestimation30. Fifth, we estimated annual results assum-
ing an hypothetical scenario where PM10 concentrations would
have decreased during one year only. Sustained reduction of air
pollution would result in larger cumulative beneﬁts for the
population. In addition to these assumptions, we used the current
EU standard and WHO target as reference levels in our assess-
ment. The EU standard, based on older evidence and conﬁrmed by
parliament in 2007, is high compared to standards adopted by
several European countries, the United States, and the new WHO
target. Although target values are regulatory instruments with
compliance requirements that differ between countries, the
revised values adopted by these countries reﬂect a more stringent
vision of protecting public health31. Adopting this more stringent
WHO target would yield beneﬁts three times larger than those
achieved by reducing air pollution to the current EU standard. For
the purpose of this study, the WHO and EU ambient limit values
are interpreted as target average population exposure. This is
consistent with the compliance approach of local authorities that
assumes that any location in the area of study area must reach
annual concentrations levels below the EU limit value. The
reference average population exposure concentration based on
modeling approaches may present some error, but we considerthe impact on the estimates low, as the same errors and
uncertainties would apply in the measure of the compliance level.
Sensitivity analysis showed that alternative assumptions
inﬂuence the central point estimate of the beneﬁts to different
degrees (Fig. 2). First, the 95%CI of the CRF is the source of the
largest uncertainty. These uncertainty bounds are on average
750% but range between 30% and 80% for the different health
outcomes. The CRF for chronic bronchitis in adults presents the
widest range. This CRF is based on only one cohort study from
North America14. Chronic symptoms have been shown to be
associated with air pollution in Switzerland32 and among women
in Germany33 and Europe34. When additional cohort studies are
available the uncertainty is likely to shrink. It should be
emphasized that the HIA estimates within the 95%CI are not all
equally likely. It is more probable that true health beneﬁts lay
closer to the point estimate than the limits of the CI. Second,
choice of CRFs can represent large uncertainties. For example, we
chose a CRF for mortality due to long-term exposure similar to the
CRF used in other European HIAs,10,35 but lower estimates have
been used in more conservative evaluations8. Third, errors in the
frequency of respiratory outcomes lead in uncertainties for cardio-
respiratory morbidity outcomes larger than for mortality and
health care outcomes but smaller than for other sources of
uncertainty. Errors could result from our choice of using
frequencies from populations for which the CRF was derived to
avoid mismatch in deﬁnitions and non transferability between
populations. For example, due to the speciﬁcity of the population
used to derive the CRF for chronic bronchitis, a cohort of non-
smokers adults aged 25 years and above from the Seventh-Day
Adventist community in the United States, we preferred using the
occurrence of cases from this population. Similarly, due to the
speciﬁcity in deﬁnitions used in the CRFs, the prevalence of acute
bronchitis in children was based on a cross-sectional study
conducted during 1992/1993 that investigated the association
between long-term exposure to air pollution and respiratory
health and allergy in Swiss children (study SCARPOL). The number
of asthma attacks per asthmatic child was also obtained from this
study. When outcome deﬁnitions in CRF studies matched more
closely with deﬁnitions of data available at the local level, we
preferred using the latter to minimize potential errors in health
frequencies. The number of asthmatics and the number of asthma
attacks per adults were obtained from the Barcelona data of the
European Community Respiratory Health Survey (ECRHS),
although the ECRHS study is limited to young adults (aged
between 20 and 44 years). The underlying number of asthmatics
was obtained from the cross-sectional Barcelona SARI study
(Estudio sobre la Salud Respiratoria en la Infancia), that derived
the prevalence of asthma based on 10,821 children aged between
7 and 8 years recruited from primary schools in the cities of
Barcelona and Sabadell. Health monitoring projects could sub-
stantially enhance the ability to estimate public health risks of
various exposures. Finally, WTP approaches rely on respondents’
ability to answer when estimating how much they are willing to
pay for small changes of risks. Analysis showed that uncertainty
around these unit values are large, averaging 50%. Taken together,
these alternative assumptions show that presenting a range of
uncertainty around the mean estimate based only on the 95%CI of
the CRF may be too simplistic. However, studies using probabil-
istic models have also shown that uncertainties associated with
the exposure-response coefﬁcient, and plausibility of the cardio-
pulmonary mortality are greater than when compared with other
uncertainties36. Considering current knowledge, our evaluation
presents a general estimate of beneﬁts.
As in other HIAs, the overall burden attributed to air pollution
was heavily driven by mortality due to long-term exposure, thus
this outcome requires further discussion4,8,10. Most of these
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approach used for other risk factors37. However, expressing results
in terms of life expectancy rather than attributable deaths is
increasingly favoured38,39. Our study expresses results using both
approaches. This change reﬂects the fact that the concept of
)attributable deaths*, and in particular the often interchangeably
used term )preventable death*, is misleading, because reducing
pollution postpones rather than prevents death. As a cohort ages,
and the beneﬁts of reducing air pollution are realized, the number
of attributable deaths will not remain constant, and gains will
sum to zero when all members of the cohort are dead39. Long-
term air pollution beneﬁts are thus more appropriately expressed
in terms of life years gained or life expectancy because life years
accumulate independently of attributable deaths19,39 (Fig. 3),
developed following methods in Miller and Hurley report,39
presents the evolution under WHO escenario.
The use of life years has considerable impact on economic
valuation. Using a published value of life year (VOLY),6,10 we
estimated that, without discounting, the total annual monetary
beneﬁts would be approximately 50% less than beneﬁts obtained
using attributable death and associated monetary values. Similar
differences have been obtained in other evaluations6. While
expressing results in terms of life years gained may be more
accurate, communicating these results to lay people is more
complex than dealing with attributable deaths. In addition, many
questions remain regarding the interpretation of long-term public
health beneﬁts of air pollution abatement strategies, including
the integration of future populations and life-time dynamics
in calculations, and the appropriateness of discounting and
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Figure 3. Evolution of the number of preventable deaths (A) and life years gained
with time (B) for the cohort of the 2004 population followed until extinction.
Reduction in mortality rates is based on the WHO air pollution reduction
scenario39.In conclusion, the results of this study indicate that the health
and economic beneﬁts of reducing air pollution in the Barcelona
metropolitan area may be substantial. These beneﬁts could only
be estimated in crude terms, due to a range of inherent
uncertainties and other methodological limitations. Despite these
limitations, local air pollution HIAs are useful tools to translate
research results into community-based evidence to protect public
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